INTRODUCTION {#s1}
============

Chronic lymphocytic leukemia (CLL) is a disease of nonproliferating and mature-appearing B lymphocytes. Most patients with CLL are elderly; just 10% are aged less than 50 years. In the evaluation of the prognosis of patients with CLL, mutations and cytogenetic abnormalities are crucial and independent markers in addition to clinical classifications \[[@ref1],[@ref2]\].

Insulin-like growth factor (IGF) has a pivotal role in the normal development of fetuses and children. In adulthood, this growth factor has a role in the inhibition of cell proliferation and apoptosis, in addition to its role in cellular metabolism. IGF-1 is a small peptide hormone that has mitogenic and antiapoptotic effects, but IGF-binding protein 3 (IGFBP-3) has an antiproliferative effect and negates the mitogenic effects of IGF-1 by stimulating apoptosis. In several types of tumors, it has been shown that IGF-1 levels are increased and IGFBP-3 levels are decreased \[[@ref3],[@ref4]\].

In this study, we investigated plasma levels of both IGF-1 and IGFBP-3 in patients with CLL compared with controls and we compared these plasma levels according to prognostic factors.

MATERIALS AND METHODS {#s2}
=====================

Patients who were newly diagnosed with CLL at the Haseki Training and Research Hospital and healthy volunteers were included in this study. Patients with the following conditions were excluded from the study: chronic renal disease, decompensated heart failure, chronic hepatitis, coronary artery disease, diabetes mellitus with organ damage or uncontrolled plasma glucose levels, chronic inflammatory disease, and major trauma in the last the year. Twenty-one volunteers were included in the control group.

Plasma samples were obtained after centrifugation at 3500 rpm for 8 min and stored at -80 °C until analysis. Plasma IGF-I detection was performed using an ELISA kit (DRG International, USA) in accordance with the manufacturer's protocol. The sensitivity of the kit was 0.15 ng/mL. IGFBP-3 levels were measured using a BioSource ELISA Kit with solid-phase enzyme immunoassay (BioSource, Belgium). The analytical sensitivity of the kit was 10 μg/mL. Samples were measured using an ELISA microplate reader (DV-990 BV4, N.T. Laboratory, Italy).

Statistical analysis was conducted using SPSS 17.0 for Windows (SPSS Inc., Chicago, IL, USA). The Kolmogorov-Smirnov test was used to determine whether the samples were from a population with normal distribution. In the comparison of values between two groups, Student's t-test was used if the group was distributed normally. If the group was not normally distributed, the Mann-Whitney U test was used. In the analysis of proportional data, the chi-square test was used. Pearson and Spearman correlation tests were used to compare numerical parameters. One-way ANOVA testing was used to compare more than two groups; post hoc Bonferroni testing was used for multiple comparisons. In all statistical assessments, the cut-off level of statistical significance was assumed as p\<0.05.

Study assessment and methods were approved by the local institutional ethics committee. Patient demographics and laboratory data were obtained from patient records upon obtaining oral informed consent from the patients and their information was recorded.

RESULTS {#s3}
=======

Forty-three patients \[16 women (37%) and 27 men (63%)\] were enrolled in the study. Twenty-one control subjects who were demographically compatible (11 women, 10 men) were included in the control group. The median age of the patient and control groups was 65±9 years (range: 18-63 years) and 68±8 years (range: 18-63 years), respectively. There was no statistical demographic difference between the two groups (p\>0.05).

Among the patients, 44% (n=19) had CLL of Rai stage 0, 11% (n=5) stage I, 20% (n=9) stage II, 16% (n=7) stage III, and 6% (n=3) stage IV.

Compared with the control group, IGF-1 levels were found to be higher in the study group (531±246 ng/mL), and IGF-1 levels were also detected to be subsequently higher in every Rai stage (Rai stage 0, 1... etc.). However, this difference was not statistically significant (p\>0.05). IGFBP-3 levels were found lower in the study group (3890±324 ng/mL) and IGFBP-3 levels were also found lower in each sequential Rai stage (Rai stage 0, 1... etc.), but this was not statistically significant (p\>0.05). The IGF-I/IGFBP-3 ratio was higher in the study group (0.32±0.60 ng/mL), although the difference was not statistically significant (p=0.5) ([Table 1](#t1){ref-type="table"}).

In patients with CLL, we observed that IGF-1 levels had a positive correlation with Rai stages (Rs=0.411; p\<0.01). The same correlation was not observed for IGFBP-3 levels (Rs=-0.075; p=0.6). IGF-1 levels in the patients with CLL appeared to increase in parallel with more advanced Rai stages. There were no significant differences among Rai stages (p=0.105). When IGFBP-3 levels were compared according to stage, there were also no statistical significant differences (p=0.3) ([Figures 1](#f1){ref-type="fig"} and [2](#f2){ref-type="fig"}).

DISCUSSION {#s4}
==========

The IGF system plays a pivotal role in normal growth throughout fetal and childhood development. In adult life, this system continues to function by regulating normal cellular metabolism, proliferation, and differentiation and it protects against apoptotic signals. However, aberrant stimulation can contribute to the development and progression of malignant growth \[[@ref4],[@ref5],[@ref6]\].

It has been shown in cell cultures that IGFBP-3 inhibits DNA synthesis without IGF. It has been claimed that IGFBP-3 may link p53 to potential novel autocrine/paracrine signaling pathways and to processes regulated by or dependent on IGF(s), such as cellular growth, transformation, and survival. It has also been asserted that induction of IGFBP-3 gene expression by wild-type, but not mutant, p53 was associated with enhanced secretion of an active form of IGFBP-3 capable of inhibiting mitogenic signaling by IGF-1 \[[@ref7]\].

Many studies have reported that high levels of IGF-I, low levels of IGFBP-3, or increments of the molar ratio of IGF-I/IGFBP-3 were associated with various types of cancers \[[@ref8],[@ref9],[@ref10],[@ref11]\].

In our study, the mean plasma IGF-I levels of the patients were found higher than those of the control group, but the difference was not statistically significant. Plasma IGFBP-3 level was lower than in the control group, but this was also not statistically significant. However, plasma IGF level increments were in parallel with Rai stages. A reverse correlation was not observed for IGFBP-3 levels.

Molica et al. measured serum levels of IGF-1 and IGFBP-3 in 77 patients with CLL and found them to be statistically significantly lower than in the control group. However, no significant correlation was found between serum levels of either IGF-1 or IGFBP-3 and clinicohematologic variables including age, sex, Rai clinical stages, serum levels of lactate dehydrogenase and beta-2 microglobulin, peripheral blood lymphocyte count, and lymphocyte doubling time \[[@ref11]\].

In our study IGF-1 and IGFBP-3 levels were lower in patients with Rai stage 0 compared with the control group. Although IGF-1 levels were found lower in early stages, they increased significantly in parallel with more advanced Rai stages.

In conclusion, plasma IGF-I levels in CLL patients were found higher than in the control group and plasma IGFBP-3 levels were lower. However, neither result was statistically significant. The increments of plasma IGF-1 level were in parallel with Rai staging.

These results suggest that plasma IGF-1 levels in patients with CLL are correlated with tumor burden and Rai staging and therefore might be a valuable prognostic factor. Further comprehensive studies are required to support our results.
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